anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Novel active compositions having antimicrobial and anti-inflammatory activity are described, the activity provided by an active component prepared in a suspension, the active component being at least a single chain fatty acid having a carbon length of 12, or between 12 and no more than 18. The fatty acid may be esterified and/or ethylated or methylated. As an antimicrobial the active component has activity against one or more microorganisms including Staphylococcus spp., Streptococcus spp., Mycobacterium spp., Clostridium spp., and Candida spp., with an MIC as low as 0.0018 μg/ml. As an anti-inflammatory, it is at least as or is more effective than cyclosporine in preventing T-cell proliferation in response to a trigger, such as stimulation by the one or more microorganisms. The active component is more active when combined with a phospholipid (e.g., lecithin, phosphatidylcholine) and caused to form liposomal nanoparticles. It is also more active when caused to form coated liposomal nanoparticles. Compositions with said active components may be provided internally and/or topically on a surface or on skin.
Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 14 days for 8 doses, then every 28 days for a total of 2 years in the absence of disease progression or unacceptable toxicity.
Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
Participants first received placebo nasal spray. After a washout period of 2 weeks, they then receive oxytocin (24 IU).
A layered structure is constructed along a cross-sectional edge of required cross section. It comprises local components of m and n layers, m and n being whole numbers of which m is the greater. An Independent claim is included for the method of making the plaster. Preferred features: For the purposes of this patent, perforation means cut through, but not necessarily separated. For therapeutic purposes the plaster comprises a substrate (1) and a layer (2) holding active material. Where necessary a release control layer (3) and/or an adhesive layer and/or a detachable protective backing (5) are included. One of the layers at least is perforated or sectional. It has regions of diverse construction. The integral substrate is an elastic sheet. Sections (10) of the plaster each comprise independent microsystems of identical construction. Each is attached to a highly-resilient sheet forming a substrate. A perforated layer is expansible or elastic. Directional expansibility is 0.5-95%, preferably 5-20%. The perforated sheet is non expansible and/or inert and/or a water vapor barrier. Further layer(s) are perforated. A further layer and film have congruent or non-congruent stacking sections. The elastic layer is a film. Layer detail is further elaborated and thicknesses are quantified.
The present invention relates to a method for modifying liver cells such that they produce and store insulin. In addition, the invention relates to these modified cells and their use in the treatment of insulin-dependant diabetes. Accordingly the present invention provides a modified human hepatic cell characterised in that said cell is insulin-producing. In addition, the present invention provides a method for making an insulin-producing cell line comprising the steps of: (i.) isolating human hepatic progenitor cells; (ii.) introducing a construct for expressing Pdx 1 into said cells; and (iii.) selecting and isolating cells which express Pdx 1.
Participants should move their arms with restricted movements on the first postoperative day, with maximum amplitude of 90º for flexion and abduction of the shoulder, until withdrawal surgical points. Actual hospital's routine.
Two-year oral carcinogenicity studies of nintedanib in rats and mice have not revealed any evidence of carcinogenic potential. Nintedanib was dosed up to 10 and 30 mg/kg/day in rats and mice, respectively. These doses were less than and approximately 4 times the MRHD on a plasma drug AUC basis.

Nintedanib was negative for genotoxicity in the in vitro bacterial reverse mutation assay, the mouse lymphoma cell forward mutation assay, and the in vivo rat micronucleus assay.

In rats, nintedanib reduced female fertility at exposure levels approximately 3 times the MRHD (on an AUC basis at an oral dose of 100 mg/kg/day). Effects included increases in resorption and post-implantation loss, and a decrease in gestation index. Changes in the number and size of corpora lutea in the ovaries were observed in chronic toxicity studies in rats and mice. An increase in the number of females with resorptions only was observed at exposures approximately equal to the MRHD (on an AUC basis at an oral dose of 20 mg/kg/day). Nintedanib had no effects on male fertility in rats at exposure levels approximately 3 times the MRHD (on an AUC basis at an oral dose of 100 mg/kg/day).
Participants in this group match an enrolled PKU participant in terms of age, gender, and body mass index class. They will participate in a single study visit and will not be given BH4.
A clinical virtual simulator contains an interactive medical case depicting an acutely ill patient seeking care at the emergency department. The case will be delivered in small groups (up to 6 participants) in sessions lasting up to 20 minutes. After the simulation has been completed, a feedback session lasting up to 30 minutes will be delivered as well.
<P>PROBLEM TO BE SOLVED: To provide a microgel for the oral cavity which has a low fluidity, is easy and safe to use, and efficiently delivers effective components.  <P>SOLUTION: The microgel for the oral cavity includes a cationic bactericide and agar. The content of the agar is 0.3-3 mass%. The microgel for the oral cavity (or a composition for the oral cavity containing the microgel) is easy to be adsorbed on the surface of the teeth, hard to drip, easily penetrates between teeth and teeth and gums. The cationic bactericide is easy to disperse and elute.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Psychotic experiences have been shown to be comparable in borderline personality disorder (BPD) and schizophrenia. Preliminary evidence suggests differences in the impact of psychotic experiences on daily functioning. Therefore, in this study, we aimed to investigate the role of psychotic experiences in daily functioning in BPD compared with schizophrenia. We performed post hoc analyses on data from 23 inpatients with BPD and 21 inpatients with schizophrenia, for whom results from the Psychotic Symptom Rating Scales were available. No differences were found in frequency, intensity, and disruption of life in relation to auditory verbal hallucinations and the amount of preoccupation and conviction with regard to delusions. Significant differences were found in the disruption of life due to delusions. The results emphasize that the quality of psychotic experiences in BPD and schizophrenia is comparable, but the impact of delusions on daily life is different, which may improve differential diagnosis.
Participants in this study arm will be provided with a diet low in free sugars. This intervention replaces the habitual diet with a low "free sugars" diet (goal of \<3% of total calories).
Treatment E: Hydromorphone IR 4 mg: 1 × hydromorphone IR 4 mg tablet (encapsulated) and 7 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
Baclofen injection is indicated for use in the management of severe spasticity in adult and pediatric patients age 4 years and above. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of baclofen injection via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. Baclofen injection is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only with the Medtronic SynchroMed® II Programmable Pump or other pumps labeled for intrathecal administration of baclofen injection [see Clinical Studies (14)].

Prior to implantation of a device for chronic intrathecal infusion of baclofen injection, patients must show a response to baclofen injection in a screening trial [see Dosage and Administration (2.2)].
This is a pre-post observational study which will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients. This study was reviewed and approved by the Albany College of Pharmacy and Health Sciences Institutional Review Board. Potential subjects will be identified via a computerized text search of the medication and problem fields of patient electronic medical records (EMR). Search terms include exenatide, Bydureon, liraglutide, Victoza, GLP-1 agonist, NPH, Lantus, Levemir, and T2DM. Individual records of identified patients will be reviewed to ascertain if all applicable study criteria are met. Inclusion criteria are: T2DM, age 18-85 years, documentation of basal insulin therapy for minimum of one year prior to GLP-1 initiation, and addition of weekly exenatide or daily liraglutide added to basal insulin therapy for a minimum of 12 months. Exclusion criteria include: Type 1 diabetes, patients receiving prescription medications for weight loss, and initiation of additional diabetes, hypertension or cholesterol drugs during the follow-up period.

A data collection form will be utilized to collect the following patient information: baseline demographic information (gender, age, height, weight), duration of diabetes, medications, laboratory information (HbA1C, cholesterol profile \[total cholesterol, triglycerides, LDL-C, HDL-C\]), and blood pressure. The primary study outcome is change in HbA1C from baseline to 12 months after GLP-1 therapy is added to basal insulin therapy. A separate analysis including patients who do not complete 12 months of GLP-1 therapy will also be performed. Secondary outcomes are change in weight, percentage of patients achieving an A1C of \<7%, changes in systolic and diastolic blood pressures, changes in lipid parameters (TC, LDL-C, HDL-C, and TG's), and reductions in number/doses of diabetes, blood pressure, and lipid lowering medications. Safety will be assessed by collection of reported adverse effects. Medication compliance will be assessed by review of an insurance data base record of refills.
The invention relates to an oxygen supply method for supplying oxygen to passengers in transportation, which comprises the following steps: the basic information of the passengers is collected before or when the passengers enter the vehicle and stored. The basic information includes facial features of the passenger and health indications. And II, acquiring real-time information of the passengers at random in the whole transportation process, wherein the real-time information comprises the facial features and health indications of the passengers. And III, identifying the passengers through the face features after the real-time information in the step II is acquired every time, and comparing the health indication in the real-time information with the health indication in the basic information. And IV, when the comparison result in the step III exceeds a threshold value, providing oxygen supply suggestions for passengers or directly supplying oxygen to the passengers. According to the invention, the unobvious symptoms at the initial stage of hypoxia are highlighted by basic information acquisition and real-time information comparison, individual differences of people are eliminated to the greatest extent, and the hypoxia passenger identification efficiency and the oxygen supply efficiency are higher.
Mantram Repetition Program for PTSD delivered in this study as 6-week, 90-minute per week that targeted PTSD symptoms. It was offered as an adjunct to usual care consisting of medication and case-management.
Carotid-cavernous fistulas are rare entity with incidence of less than 1%, refers to abnormal connections between the carotid artery and cavernous sinus. Indirect types usually occur in elderly female patients and can resolve spontaneously with conservative management like external manual compression of the carotid artery. We report a case of 65-year-old female who presented with complaints of redness, proptosis, chemosis, headache and ophthalmoplegia in her right eye. Digital subtraction angiography revealed Barrow type B indirect carotid-cavernous fistulas. External manual carotid compression was done after which her symptoms improved significantly. Thus, indirect type carotid-cavernous fistulas can occur spontaneously and could be a sight threatening condition especially in elderly females but can resolve with conservative management.
Two-visit root canal treatment for children reduce the time of visits and the by-chair time in comparison with the three-visit root canal treatment. However, it is not clear whether two-visit root canal treatment increase the risk of complications. This study aimed to evaluate the clinical effects and post-operative pain intensity after the root canal treatment between two-visit and three-visit groups in primary molars from children.106 patients were screened for eligibility, of which 74 went back to the preservation visit. Therefore, 74 primary molars from 74 children that diagnosed with chronic pulp and periodontal tissue diseases in the clinics of pediatric dentistry were retrospectively analyzed, in which 37 in the two-visit group and 37 in the three-visit group. The total effective rate and postoperative pain intensity were assessed after treatment and all statistical data were carried out with SPSS software.The average age of children in the two-visit and three-visit groups was 6.4 and 7.0, respectively, with no significant difference (p = 0.056). The two-visit group consisted of 59.5% male and 40.5% female children, while the three-visit group consisted of 56.8% male children and 43.2% female children (p = 0.813). Two months after treatment, the total effective rate in the three-visit group was 97.30%, a little higher than that in the two-visit group (94.59%), but with no significant difference (p = 0.201). Besides, there was also no significant difference in pain intensity between the two-visit and three-visit groups (p = 0.692). Therefore, there were no significant difference of total effective rate and pain intensity in root canal treatment between the two-visit and three-visit groups in primary molars from children.
The present invention relates to novel Pyrrole-Type compounds (I), compositions comprising Pyrrole-Type compounds, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Pyrrole-Type compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell. The present invention also relates to novel Pyrrole-Type compounds, compositions, and methods useful for treating or preventing a viral infection. The compounds, compositions, and methods of the invention are also useful for inhibiting the replication and/or infectivity of a virus. The present invention also relates to novel Pyrrole-Type compounds, compositions, and methods useful for causing immunosuppression. The present invention also relates to novel Pyrrole-Type compounds, compositions, and methods useful for treating or preventing an autoimmune disease.
Group B (Conventional therapy) Conventional Physical therapy i.e. Ultrasonic therapy 3 min 1 MHz, TENS 10 min, hot pack for 10 min and back strengthening exercises.
Stable parenteral formulations of busulfan safe for parenteral administration. An HPLC assay for busulfan sensitive enough to dependably quantitate concentrations in plasma as low as approximately 100 ng/ml was developed. The stability of these formulations was investigated to select preparations providing desirable plasma pharmacokinetic parameters with parenteral versus oral administration. In addition, quantitative extraction technology was established for reliable quantification of bulsulfan in plasma samples after both oral and parenteral drug administration. When administered to experimental animals, the parenteral busulfan formulation yielded significantly higher plasma drug concentrations and higher area under the plasma concentration vs. time curve than did the oral (standard) tablet preparation. The improved bioavailability of the parenteral formulation optimizes high dose busulfan thepary against malignant disease and improves the safety of such therapy.
LPLC refers to "Low Pressure Laparoscopic Cholecystectomy". In this arm, the pneumoperitoneum pressure is set as 10mmHg.
Objective: The investigators aim to evaluate the acute effects of aerobic, resistance and combined (aerobic+ resistance) exercise on the BP, hemodynamic and inflammatory parameters, as well as arterial stiffness in RHTN patients compared to mild to moderate hypertensive (HTN) and normotensive (NT) subjects. Design and Methods: This interventional, randomized, single-blind, crossover study will be conducted in 30 patients (RHTN=10, HTN=10, and NT=10) regularly followed in the Outpatient Resistant Hypertension Clinic at UNICAMP- Brazil. All the subjects will be submitted to a previous adaptation of physical activity, especially to determine the load to be implemented in each patient. Then, the modalities of physical exercises (aerobic, resistance and combined) will be randomly performed in three isolated sessions, which will consist of: a) Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test; b) resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes; c) combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes. Body composition (plethysmography) and cardiorespiratory functional capacity (ergometry) will be determined before the physical training. In addition, the investigators will assess BP recording (by Finometer, office and ambulatory BP), arterial stiffness (by pulse wave velocity, Sphygmocor CPV system), plasma biomarkers (TNF-α, interleukins -1, -6, -10, and -17 by ELISA) in pre and post periods of each physical exercise. Results: Since the physical exercise in its different modalities provides chronic effects on BP in HTN patients, the investigators hypothesized that the isolated (aerobic and resistance) and combined exercise can acutely promote changes in BP levels in RHTN patients when compared to the participants counterparts. Secondarily, some biological mechanisms related to BP control (vascular function and cytokines production) may also be involved in these possible alterations. Conclusion: The investigators expect to define whether a physical exercise program applied to RHTN patients has medical relevance in a realistic clinical setting. These findings may guide the prescription of physical activity as an additional therapeutic approach, in order to decrease the cardiovascular risk associated to these subjects.
The present disclosure relates to a method. The method includes accessing data having one or more segmented images identifying one or more lesions and/or a plurality of blood vessels associated with the lesions. Respective ones of the blood vessels correspond to one or more centerlines and one or more constituent branches associated with the one or more lesions. The one or more segmented images are derived from one or more radiological images of a patient having cancer. One or more vascular radiology features are extracted using the centerlines, the constituent branches, and the one or more lesions. The one or more vascular radiology features relate to a quantification of the plurality of blood vessels or a shape of the plurality of blood vessels. The one or more vascular radiology features are used to determine a medical prediction associated with an outcome of the patient to cyclin-dependent kinase (CDK) inhibitor therapy.
BACKGROUND: Intermittent self-catheterization (ISC) is widely considered the gold standard for treating patients with neurogenic bladder (NB). Healthcare professionals and catheter users must optimize ISC care to improve patients' quality of life. To achieve this, the Intermittent Self-Catheterization Questionnaire (ISC-Q) is a valuable tool with clear and easy-to-understand items. However, this scale has yet to be adapted for use in China, and its reliability and validity need to be tested through cross-cultural adaptation.
OBJECTIVES: The objective of this study was to culturally adapt the ISC-Q and develop the Chinese version of the ISC-Q (C-ISC-Q), and assess its reliability and validity among patients with NB.
METHODS: With the authorization of the ISC-Q author, the Beaton mode was used to adapt the scale cross-culturally. The study was conducted from June 2020 to June 2021 in three phases: committee-based translation from English to Chinese, Delphi expert consultations (n = 5) for cultural adaptation, and a cross-sectional study (n = 149) for validation.
RESULTS: The C-ISC-Q has 24 items and four dimensions. The critical ratio of each item is over 3.0, and the correlation coefficient between each item and the scale's total score is above 0.4. The Cronbach's α value for the scale is 0.930, and for each dimension, it is between 0.870-0.92. The retest reliability for the scale is 0.894, and for each dimension is between 0.751-0.889. The content validity at the item level ranges from 0.8~1.0, and at the scale level is 0.9. The criterion-related validity of the scale was -0.708, and the correlation for each dimension was 0.329-0.624. The principal component analysis identified four common factors, with a cumulative contribution rate of 67.846%.
CONCLUSIONS: The C-ISC-Q is culturally sensitive, reliable, and valid to measure the quality of life for patients with NB. It can assist nurses and researchers in tailoring strategies to enhance the quality of life for patients with NB.
Participants with MCI who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
Eosinophilic pneumonia has been reported in patients receiving CUBICIN [see Adverse Reactions (6.2)]. In reported cases associated with CUBICIN, patients developed fever, dyspnea with hypoxic respiratory insufficiency, and diffuse pulmonary infiltrates or organizing pneumonia. In general, patients developed eosinophilic pneumonia 2 to 4 weeks after starting CUBICIN and improved when CUBICIN was discontinued and steroid therapy was initiated. Recurrence of eosinophilic pneumonia upon re-exposure has been reported. Patients who develop these signs and symptoms while receiving CUBICIN RF should undergo prompt medical evaluation, and CUBICIN RF should be discontinued immediately. Treatment with systemic steroids is recommended.